Stock Recommendations for the Week of September 28, 2026
Investors looking for stock recommendations for the week starting September 28, 2026, may consider Pearl Global and Indegene, as highlighted by the Motilal Oswal Wealth Management Research Desk. Pearl Global is expected to enhance its manufacturing capacity significantly, with plans to increase production from approximately 108 million pieces to between 120 and 140 million by FY28, and further to 170 to 175 million by FY30. This expansion is projected to occur at around 80% utilization. The company aims to increase its wallet share from existing customers, diversify its product portfolio, and expand into key manufacturing geographies, all of which are anticipated to drive growth.
Pearl Global plans to invest between Rs 6.75 billion and Rs 7.25 billion through FY30, allocating Rs 3.25 billion to Rs 3.50 billion for capacity expansion and the remainder for investments in knitting and dyeing. The company aims to increase its knitted products from about 26% to 35% of its capacity while reducing reliance on washing outsourcing from approximately 60% to between 20% and 25%. These strategic moves are expected to support margin expansion, with revenue, EBITDA, and PAT projected to grow at CAGRs of 17%, 32%, and 38% respectively over FY26-FY28. EBITDA margins are anticipated to improve to between 12% and 14%, with a return on capital employed (RoCE) of 22% to 25%. Management targets revenues of Rs 90 billion to Rs 100 billion by FY30, reflecting a growth of 16% to 18% from FY26.
For Your Trading Desk
Sponsor Spike Success.
Indegene is also positioned to benefit from the increasing trend of pharmaceutical outsourcing. As drug pipelines expand and clinical complexities rise, life sciences companies are focusing their internal resources on core research and development. Indegene's integrated platform encompasses clinical, regulatory, medical, and commercial operations, covering the entire commercialization lifecycle from evidence generation to lifecycle optimization, supported by a unified data, analytics, and technology framework.
Indegene's Strong Growth Projections Lead to Upgraded BUY Recommendation
Operationally, Indegene ranks in the top quartile, boasting superior revenue per employee. The company anticipates a CAGR of approximately 19% in revenue, 29% in EBITDA, and 27% in PAT over FY26-28. The EBITDA margin is expected to recover to between 19% and 20% by the fourth quarter of FY27, aided by operating leverage. Given these factors, the recommendation for Indegene has been upgraded to a BUY.




